00512 GRANDPHARMA
- 4.990
- -0.070-1.38%
GRANDPHARMA News
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
Yuanda Pharmaceutical (00512.HK) received Zhou Chao an increase of 49,500 common shares worth approximately HK$250,000
On May 13, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 13, Zhou Chao increased his common stock holdings of $Yuanda Pharmaceutical (00512.HK) by $49,500 at an average price of HK$5.05 per share on May 10, worth about HK$250,000. After increasing his holdings, Zhou Chao's latest shareholding was 312,500 shares, and the good position ratio was 0.00%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors and top executives of listed companies are required
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Zhitong Hong Kong Shareholders' Rights Disclosure | May 10
Disclosure of Hong Kong Stock Shareholders' Rights | May 10
Yuanda Pharmaceutical (00512.HK) First Coverage Report: Multiple Businesses Go Hand in Hand to Lead Development with Nuclear Drugs
Key points of the report: A pharmaceutical company with a long history. The three major sectors have gone hand in hand and the company has a rich historical heritage. Formerly known as Wuhan Pharmaceutical Factory, it joined China Yuanda Group in 2002 and went public in Hong Kong in 2008. The company actively mergers and acquisitions and undertakes globalization
Yuanda Pharmaceutical (00512.HK) was granted an increase of 100,000 common shares by Tang Weikun, worth approximately HK$488,700
On May 9, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 9, Tang Weikun increased his shareholding of $100,000 common shares of $Yuanda Pharmaceutical (00512.HK) at an average price of HK$4.887 per share on May 9, worth about HK$488,700. After the increase in holdings, Tang Weikun's latest shareholding was 515,000 shares, and the good position ratio was 0.00%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors and top executives of listed companies are required
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Hong Kong Stock Concept Tracking | China's Nuclear Medicine Industry Attracts Attention (with concept stocks), the key technology for batch online irradiation production of isotopes
Various short-half-life medical isotopes that are currently in short supply in China will enter the large-scale production stage after the supporting plant is completed and put into operation in the second half of this year.
Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump
Grand Pharmaceutical Group (HKG:0512) recorded a 10% decline in attributable profit for the year ended Dec. 31, 2023, to HK$1.88 billion from HK$2.08 billion during the year-ago period, according to t
遠大醫藥：2023年年報
Changes in Hong Kong stocks | Yuanda Pharmaceutical (00512.HK) rose more than 6% in the intraday period, domestic carbon-14 isotopes to supply domestic nuclear drugs to the market at the end of the year ushered in new opportunities
Yuanda Pharmaceutical (00512.HK) rose more than 6% in the intraday period. As of press release, it rose 4.94% to HK$4.25, with a turnover of HK$21.15,900.
Hong Kong Stock Concept Tracking | China's first mass production of carbon-14 isotope domestically produced nuclear drugs ushered in new opportunities (with concept stocks)
At 13:48 on April 20, after two years of core irradiation, the first carbon-14 target was successfully removed from the Qinshan Nuclear Power Heavy Water Reactor Unit of China Nuclear Power Investment Holdings under the China Nuclear Power Group. This was the first time that China mass-produced carbon-14 isotopes, solving the problem that domestic carbon-14 isotopes are dependent on imports, and fully localizing carbon-14 supply. Carbon-14 is a radioactive isotope of carbon and is widely used as a tracer. Helicobacter pylori testing is its most representative use. In addition, fields such as pharmacokinetic research and beta-ray environmental monitoring systems also require carbon-14. Previously
Yuanda Pharmaceutical (00512.HK) received 95,000 additional shares from Chairman Tang Weikun
Gelonghui, April 22丨According to the latest equity disclosure data of the Stock Exchange, on April 19, 2024, Yuanda Pharmaceutical (00512.HK) was granted an increase of 95,000 shares at an average price of HK$3.91 per share on the market, involving approximately HK$371,500. After the increase in holdings, Tang Weikun's latest shareholding was 415,000 shares.
Yuanda Pharmaceutical (00512.HK) was granted an increase of 95,000 shares of common shares by Tang Weikun, worth approximately HK$371,500
On April 19, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 19, Tang Weikun increased his common share holdings of $Yuanda Pharmaceutical (00512.HK) by $95,000 at an average price of HK$3.91 per share on April 19, worth about HK$371,500. After the increase in holdings, Tang Weikun's latest shareholding was 415,000 shares, and the good position ratio was 0.00%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors and top executives of listed companies
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Yuanda Pharmaceutical (00512.HK) was increased by 101,000 shares by Executive Director Zhou Chao
Gelonghui, April 10 | According to the latest equity disclosure data of the Stock Exchange, on April 8, 2024, Yuanda Pharmaceutical (00512.HK) was granted an increase of 101,000 shares by Executive Director Zhou Chao at an average price of HK$3955 per share on the market, involving about HK$39,500. After increasing his holdings, Zhou Chao's latest shareholding was 263,000 shares.
Yuanda Pharmaceutical (00512.HK) received Zhou Chao an increase of 101,000 common shares worth approximately HK$39,500
On April 9, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 9, Zhou Chao increased his common stock holdings of $101,000 at an average price of HK$3955 per share on April 8, worth about HK$39,500. After increasing his holdings, Zhou Chao's latest shareholding was 263,000 shares, and the good position ratio was 0.00%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors and top executives of listed companies are required
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Analysis
Price Target
No Data
